Market Research Report
GLOBAL DRUG DISCOVERY MARKET FORECAST 2018-2026
|Published by||Inkwood Research||Product code||607157|
|Published||Content info||140 Pages
Delivery time: 2-3 business days
|GLOBAL DRUG DISCOVERY MARKET FORECAST 2018-2026|
|Published: February 25, 2018||Content info: 140 Pages||
Propelled by factors like the low performance of branded drugs as compared to generic drugs and rising spending on healthcare and research, the global drug discovery market is expected to make a leap of 9.73% CAGR, increasing its revenue from $ 36.7 billion to $83.6 billion between the forecast years of 2018-2026.
Technology-wise, the global drug discovery market is segmented into Protein Microarrays, QPCR, Mass Spectrometry, DNA Microarrays, High Throughput Screening, Protein and Nucleic Acid Isolation, Gel Electrophoresis, Chromatography, and Other Technologies. Extensive R&D for new product launches can be viewed as major opportunities for the market to expand.
North America, Asia-Pacific, Europe and Rest of World are the geographical segments of this market. By the end of the forecast period, the North American market is anticipated to account for the lion's share of the global market. The U.S is expected to be a major contributor to this region, driven by high healthcare spending and growing lifestyle oriented diseases. Also, the Asia-Pacific market is predicted to register the fastest growth driven by high investments and growing R&D.
Noted players in the global drug discovery market include Bayer Ag, AstraZeneca Plc, Boehringer Ingelheim, F. Hoffmann-La Roche Ltd, Eli Lily, GlaxoSmithKline Llc, Merck & Co. Inc, Sanofi and Pfizer Inc.